Cargando…
B- and T-cell acute lymphoblastic leukemias evade chemotherapy at distinct sites in the bone marrow
Persistence of residual disease after induction chemotherapy is a strong predictor of relapse in acute lymphoblastic leukemia (ALL). The bone marrow microenvironment may support escape from treatment. Using three-dimensional fluorescence imaging of ten primary ALL xenografts we identified sites of p...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153534/ https://www.ncbi.nlm.nih.gov/pubmed/36325888 http://dx.doi.org/10.3324/haematol.2021.280451 |
_version_ | 1785035948105400320 |
---|---|
author | Barz, Malwine J. Behrmann, Lena Capron, Danaëlle Zuchtriegel, Gabriele Steffen, Fabio D. Kunz, Leo Zhang, Yang Vermeerbergen, Iria Jimenez Marovca, Blerim Kirschmann, Moritz Zech, Antonia Nombela-Arrieta, César Ziegler, Urs Schroeder, Timm Bornhauser, Beat Bourquin, Jean-Pierre |
author_facet | Barz, Malwine J. Behrmann, Lena Capron, Danaëlle Zuchtriegel, Gabriele Steffen, Fabio D. Kunz, Leo Zhang, Yang Vermeerbergen, Iria Jimenez Marovca, Blerim Kirschmann, Moritz Zech, Antonia Nombela-Arrieta, César Ziegler, Urs Schroeder, Timm Bornhauser, Beat Bourquin, Jean-Pierre |
author_sort | Barz, Malwine J. |
collection | PubMed |
description | Persistence of residual disease after induction chemotherapy is a strong predictor of relapse in acute lymphoblastic leukemia (ALL). The bone marrow microenvironment may support escape from treatment. Using three-dimensional fluorescence imaging of ten primary ALL xenografts we identified sites of predilection in the bone marrow for resistance to induction with dexamethasone, vincristine and doxorubicin. We detected B-cell precursor ALL cells predominantly in the perisinusoidal space at early engraftment and after chemotherapy. The spatial distribution of T-ALL cells was more widespread with contacts to endosteum, nestin(+) pericytes and sinusoids. Dispersion of T-ALL cells in the bone marrow increased under chemotherapeutic pressure. A subset of slowly dividing ALL cells was transiently detected upon shortterm chemotherapy, but not at residual disease after chemotherapy, challenging the notion that ALL cells escape treatment by direct induction of a dormant state in the niche. These lineage-dependent differences point to niche interactions that may be more specifically exploitable to improve treatment. |
format | Online Article Text |
id | pubmed-10153534 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Fondazione Ferrata Storti |
record_format | MEDLINE/PubMed |
spelling | pubmed-101535342023-05-03 B- and T-cell acute lymphoblastic leukemias evade chemotherapy at distinct sites in the bone marrow Barz, Malwine J. Behrmann, Lena Capron, Danaëlle Zuchtriegel, Gabriele Steffen, Fabio D. Kunz, Leo Zhang, Yang Vermeerbergen, Iria Jimenez Marovca, Blerim Kirschmann, Moritz Zech, Antonia Nombela-Arrieta, César Ziegler, Urs Schroeder, Timm Bornhauser, Beat Bourquin, Jean-Pierre Haematologica ARTICLE - Acute Lymphoblastic Leukemia Persistence of residual disease after induction chemotherapy is a strong predictor of relapse in acute lymphoblastic leukemia (ALL). The bone marrow microenvironment may support escape from treatment. Using three-dimensional fluorescence imaging of ten primary ALL xenografts we identified sites of predilection in the bone marrow for resistance to induction with dexamethasone, vincristine and doxorubicin. We detected B-cell precursor ALL cells predominantly in the perisinusoidal space at early engraftment and after chemotherapy. The spatial distribution of T-ALL cells was more widespread with contacts to endosteum, nestin(+) pericytes and sinusoids. Dispersion of T-ALL cells in the bone marrow increased under chemotherapeutic pressure. A subset of slowly dividing ALL cells was transiently detected upon shortterm chemotherapy, but not at residual disease after chemotherapy, challenging the notion that ALL cells escape treatment by direct induction of a dormant state in the niche. These lineage-dependent differences point to niche interactions that may be more specifically exploitable to improve treatment. Fondazione Ferrata Storti 2022-11-03 /pmc/articles/PMC10153534/ /pubmed/36325888 http://dx.doi.org/10.3324/haematol.2021.280451 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | ARTICLE - Acute Lymphoblastic Leukemia Barz, Malwine J. Behrmann, Lena Capron, Danaëlle Zuchtriegel, Gabriele Steffen, Fabio D. Kunz, Leo Zhang, Yang Vermeerbergen, Iria Jimenez Marovca, Blerim Kirschmann, Moritz Zech, Antonia Nombela-Arrieta, César Ziegler, Urs Schroeder, Timm Bornhauser, Beat Bourquin, Jean-Pierre B- and T-cell acute lymphoblastic leukemias evade chemotherapy at distinct sites in the bone marrow |
title | B- and T-cell acute lymphoblastic leukemias evade chemotherapy at distinct sites in the bone marrow |
title_full | B- and T-cell acute lymphoblastic leukemias evade chemotherapy at distinct sites in the bone marrow |
title_fullStr | B- and T-cell acute lymphoblastic leukemias evade chemotherapy at distinct sites in the bone marrow |
title_full_unstemmed | B- and T-cell acute lymphoblastic leukemias evade chemotherapy at distinct sites in the bone marrow |
title_short | B- and T-cell acute lymphoblastic leukemias evade chemotherapy at distinct sites in the bone marrow |
title_sort | b- and t-cell acute lymphoblastic leukemias evade chemotherapy at distinct sites in the bone marrow |
topic | ARTICLE - Acute Lymphoblastic Leukemia |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153534/ https://www.ncbi.nlm.nih.gov/pubmed/36325888 http://dx.doi.org/10.3324/haematol.2021.280451 |
work_keys_str_mv | AT barzmalwinej bandtcellacutelymphoblasticleukemiasevadechemotherapyatdistinctsitesinthebonemarrow AT behrmannlena bandtcellacutelymphoblasticleukemiasevadechemotherapyatdistinctsitesinthebonemarrow AT caprondanaelle bandtcellacutelymphoblasticleukemiasevadechemotherapyatdistinctsitesinthebonemarrow AT zuchtriegelgabriele bandtcellacutelymphoblasticleukemiasevadechemotherapyatdistinctsitesinthebonemarrow AT steffenfabiod bandtcellacutelymphoblasticleukemiasevadechemotherapyatdistinctsitesinthebonemarrow AT kunzleo bandtcellacutelymphoblasticleukemiasevadechemotherapyatdistinctsitesinthebonemarrow AT zhangyang bandtcellacutelymphoblasticleukemiasevadechemotherapyatdistinctsitesinthebonemarrow AT vermeerbergeniriajimenez bandtcellacutelymphoblasticleukemiasevadechemotherapyatdistinctsitesinthebonemarrow AT marovcablerim bandtcellacutelymphoblasticleukemiasevadechemotherapyatdistinctsitesinthebonemarrow AT kirschmannmoritz bandtcellacutelymphoblasticleukemiasevadechemotherapyatdistinctsitesinthebonemarrow AT zechantonia bandtcellacutelymphoblasticleukemiasevadechemotherapyatdistinctsitesinthebonemarrow AT nombelaarrietacesar bandtcellacutelymphoblasticleukemiasevadechemotherapyatdistinctsitesinthebonemarrow AT zieglerurs bandtcellacutelymphoblasticleukemiasevadechemotherapyatdistinctsitesinthebonemarrow AT schroedertimm bandtcellacutelymphoblasticleukemiasevadechemotherapyatdistinctsitesinthebonemarrow AT bornhauserbeat bandtcellacutelymphoblasticleukemiasevadechemotherapyatdistinctsitesinthebonemarrow AT bourquinjeanpierre bandtcellacutelymphoblasticleukemiasevadechemotherapyatdistinctsitesinthebonemarrow |